AMG 529
Alternative Names: AMG-529Latest Information Update: 28 Jun 2020
At a glance
- Originator Amgen
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Asialoglycoprotein receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in USA (IV)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in USA (SC, Injection)
- 16 Mar 2019 Pharmacodynamics, pharmacokinetics and adverse event data from a phase I trial in Cardiovascular disorders presented at the 68th Annual Scientific Session of the American College of Cardiology (AAC,